Ventripoint Announces Sponsorship for the 54th Annual Meeting of the Association of European Paediatric and Congenital Cardiology
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company“), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that they will be a Bronze level sponsor for the 54th Annual Meeting of the Association of European Paediatric and Congenital Cardiology (AEPC) to be held digitally on May 25th- 27th, 2021.
The AEPC was founded in Lyon in 1963 and has grown into a network of specialists in cardiology and related fields. The AEPC mission is to promote the knowledge and learning in the field of cardiac disease in children. The current overall membership of the Association includes 1500 paediatric cardiologists and other specialists.
The event will feature digital platforms with plenaries, parallel sessions, digital posters, and industry exhibitions. There are an expected 1000 participants, who will include international physicians, nurses, and technicians in the field of Paediatric and Congenital Cardiology.
“The AEPC Annual Meeting is an excellent opportunity to inform paediatric cardiologists, who focus on the right side of the heart, of the unique ability of the VMS+3.0 to provide accurate and reliable volumetric measurements of heart function,” stated Dr. George Adams, Executive-Chairman of Ventripoint.
Some highlights of the digital conference will include sessions on topics such as timing of pulmonary valve replacements, optimal treatment in atrial septum defect in pediatric patients, value of ultrasound in congenital heart disease, and much more.
The AEPC 2021 will be showcasing Ventripoint’s support by having a digital booth on the AEPC digital platform.
Ventripoint is dedicated to the continuous development of medical technology that provides value to clinicians in the assessment and diagnosis of cardiovascular disease.
In other news, the Company is providing an update on its financial status and the exercise of warrants and options.
The Company now has sufficient cash to cover operating and development expenses for three years at the current burn rate. In addition, the Company has no debt outstanding and a clean balance sheet.
On March 23, 2017, the Company issued 10,396,938 warrants at an exercise price of $.50. Since the last update (see NR May 9, 2021), more of these warrants have been exercised. As of today, 3,385,127 (~33%) have been exercised for gross proceeds of $1,692,564. Insiders of the Company have exercised 612,500 of these warrants representing $306,250. There are 7,011,811 outstanding warrants, which expire May 23, 2021.
There remains 1,286,666 of the warrants issued on October 2, 2019 and having an exercise price of $0.115. These warrants expire on October 2, 2022. There are no other warrants outstanding.
Since the last update (see NR May 9, 2021), the Company has had 175,000 options exercised for gross proceeds of $63,750. There are 6,498,750 options outstanding with exercise prices between $.10 to $.50. 3,188,750 of these option grants have vested and the remainder will vest over the next 2.7 years. The Company has 1,828,685 options available for future grants.
After the issuance of shares for exercised warrants (some in process), the Company will have approximately 137,553,405 common shares issued and outstanding.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Dr. George Adams
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.